At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 397 enrolled
Drug / intervention
Brolucizumab 6mg +1 moredrug
Likely dose
Brolucizumab 6mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Twelve-Month, Randomized, Double-Masked, Multicenter, Phase III, Two-Arm Study Comparing the Efficacy and Safety of Brolucizumab 6 mg Versus Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
In Brief
A Phase 3 clinical trial evaluating Brolucizumab 6mg and Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration. Completed, enrolled 397 participants across 30 sites.
Detailed Summary
To compare brolucizumab to aflibercept in Chinese patients with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartNov 2019
Primary CompletionFeb 2024
TodayJul 2026
First PostedAug 6, 2019
Enrollment StartNov 29, 2019
Primary CompletionFeb 28, 2024
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 6.9 years ago
Interventions
Brolucizumab 6mgdrug
Intravitreal injection
Aflibercept 2 mgdrug
Intravitreal injection